文献速递白血病

初治达沙替尼停药后无治疗缓解(first-line DADI 试验)

Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial.
PubMed 文献 · Lancet Haematol · 2020-01-21

这是一项在日本23家医院开展的单臂、多中心、2期试验,评估初治达沙替尼治疗至少24个月且持续深度分子学缓解的慢性期慢性髓性白血病患者停药后6个月的无分子学复发生存。

要点

  • 停药前未发生重于2级的非血液学不良事件
  • 最常见血液学不良事件为贫血(14/68,21%)

核心结论

  • 初治达沙替尼治疗至少36个月且持续深度分子学缓解的慢性髓性白血病患者可安全停药,但需更大规模试验进一步确认。

研究设计与样本

  • 单臂、多中心、2期试验,在日本23家医院开展,因入组原因提前终止(UMIN000011099)。
  • 入组新诊断慢性期慢性髓性白血病患者,需接受至少24个月达沙替尼治疗且持续深度分子学缓解。
  • 深度分子学缓解定义为BCR-ABL1/ABL1国际标准≤0·0069%且至少连续4次样本 spanning 12个月。
  • 68例进入巩固期,58例停药并纳入主要分析;安全性分析纳入全部68例接受治疗者。

主要发现

  • 58例停药患者中32例(55%)在停药6个月时处于无治疗缓解。
  • 停药前未发生重于2级的非血液学不良事件。
  • 68例治疗患者中最常见血液学不良事件为贫血(14例,21%),3例(4%)发生3级中性粒细胞减少,1例(1%)发生4级淋巴细胞减少。

关键数值与推荐

  • 停药后主要结局为6个月无分子学复发生存(即无治疗缓解)。
  • 停药条件为达沙替尼治疗至少24个月且持续深度分子学缓解(BCR-ABL1/ABL1国际标准≤0·0069%,至少连续4次样本 spanning 12个月)。
  • 入组年龄≥15岁,ECOG体能状态评分0-2,无主要器官功能障碍。
  • 解读部分提出:至少36个月治疗且持续深度分子学缓解者可考虑安全停药。

临床怎么用

  • 对初治达沙替尼治疗并获得持续深度分子学缓解的慢性期慢性髓性白血病患者,可在充分评估后考虑停药观察。
  • 停药决策需参考至少36个月治疗与持续深度分子学缓解这一试验条件,并配合密切分子学监测。

局限性

  • 单臂设计,无对照组。
  • 研究因入组原因提前终止。
  • 样本量有限(58例停药可评估),需更大规模试验进一步确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A previous dasatinib discontinuation (DADI) trial showed that 31 (49%) of 63 patients with chronic-phase chronic myeloid leukaemia who were treated with second-line or subsequent dasatinib could discontinue the drug safely. However, the safety and efficacy of discontinuing first-line dasatinib remains unclear. In this trial (the first-line DADI trial) we aimed to assess molecular relapse-free survival at 6 months after discontinuation of dasatinib in patients with chronic myeloid leukaemia who had been treated with first-line dasatinib and had maintained deep molecular response for at least 1 year. METHODS: The first-line DADI trial was a single-arm, multicentre, phase 2 trial done at 23 hospitals in Japan. Patients with newly diagnosed chronic-phase chronic myeloid leukaemia without hepatosplenomegaly and extramedullary mass, who received at least 24-month dasatinib treatment and had a sustained deep molecular response (defined as BCR-ABL1/ABL1 international scale ≤0·0069% in at least four successive samples spanning a 12 month period) were enrolled. Other eligibility criteria were an age of 15 years or older, an Eastern Cooperative Oncology Group performance status score of 0-2, and no primary organ dysfunction. The primary outcome was molecular relapse-free survival (also known as treatment-free remission) after discontinuation of dasatinib at 6 months and was analysed in all patients who completed the 12-month consolidation phase. Safety was assessed in all patients who received treatment. This study closed early due to accrual and is registered with the UMIN Clinical Trials Registry (UMIN000011099). FINDINGS: Between Sept 20, 2013 and July 12, 2016, 68 patients who had a deep molecular response after receiving first-line dasatinib for at least 24 months were enrolled and assigned to the consolidation phase. Nine patients were excluded during the consolidation phase and one patient was excluded after study completion because of meeting exclusion criteria. 58 patients discontinued dasatinib and were assessed. 32 (55%) of 58 patients had treatment-free remission at 6 months after dasatinib discontinuation, and median follow-up was 23·3 months (IQR 11·7-31·0). Treatment-free remission at 6 months was 55·2% (95% CI 43·7-69·6). No non-haematological adverse events worse than grade 2 occurred before dasatinib discontinuation. The most common haematological adverse event was anaemia (14 [21%] of 68 treated patients); three (4%) of 68 treated patients had grade 3 neutropenia and one (1%) had grade 4 lymphopenia. INTERPRETATION: Our findings suggest that dasatinib could be safely discontinued after first-line treatment in patients with chronic myeloid leukaemia who had received at least 36 months of therapy and sustained deep molecular response; however, further confirmation in larger trials is needed. FUNDING: Epidemiological and Clinical Research Information Network.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Kimura S, Imagawa J, Murai K, et al. Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2020. PMID: 31978329. doi:10.1016/S2352-3026(19)30235-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。